The Skin and Cancer Reconstructive Surgery Center (SCARS Center) in California, US, has selected SciBase Holding’s Nevisense system for the detection of skin cancer early.
This collaboration aims to expand the presence of Nevisense in the wider US market.
Nevisense is claimed to be the first-of-its-kind artificial intelligence (AI)-driven technology designed to specifically address the challenges associated with detecting the most complex type of skin cancer at point-of-care.
It offers clinicians advanced analysis of irregular moles during routine skin examinations.
Nevisense is said to be the only device approved by the US Food and Drug Administration (FDA) to detect melanoma, and is also the only technology approved by the European Medical Device Regulation to detect skin cancer in Europe.
Skin Cancer and Reconstructive Surgery Center founder and medical director Dr Simon Madorsky said: “Through our new partnership with Nevisense, we are now one of the first groups in the country to adopt AI technology that will help our clinicians improve patient outcomes.”
Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Company Profile – free
sample
Your download email will arrive shortly
We are confident about the
unique
quality of our Company Profiles. However, we want you to make the most
beneficial
decision for your business, so we offer a free sample that you can download by
submitting the below form
By GlobalData
SciBase has developed a unique point-of-care platform to non-invasively detect skin cancer and other skin conditions.
It offers Nevisense and Nevisense Go products for detecting melanoma and non-melanoma skin cancer, as well as assessing skin barrier function.
SciBase CEO Pia Renaudin said: “SciBase and the SCARS Center team are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes.
“We are continuing to broaden SciBase’s presence throughout the US, to further increase patient access to point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable.”
